The use of energy substrates, such as lactate and pyruvate, has been shown to improve synaptic function when administered during glucose deprivation. In the present study, we investigated whether prolonged incubation with monocarboxylate (pyruvate or lactate) prior rather than during glucose deprivation can also sustain synaptic and metabolic function. Pyruvate pre-incubation(3-4 h) significantly prolonged (N 25 min) the tolerance of rat hippocampal slices to delayed glucose deprivation compared to control and lactate preincubated slices, as revealed by field excitatory post synaptic potentials (fEPSPs); pre-incubation with pyruvate also reduced the marked decrease in NAD(P)H fluorescence resulting from glucose deprivation. Moreover, pyruvate exposure led to the enhancement of glycogen stores with time, compared to glucose alone (12 μmol/g tissue at 4 h vs. 3.5 μmol/g tissue). Prolonged resistance to glucose deprivation following exogenous pyruvate incubation was prevented by glycogenolysis inhibitors, suggesting that enhanced glycogen mediates the delay in synaptic activity failure. The application of an adenosine A1 receptor antagonist enhanced glycogen utilization and prolonged the time to synaptic failure, further confirming this hypothesis of the importance of glycogen. Moreover, tissue levels of ATP were also significantly maintained during glucose deprivation in pyruvate pretreated slices compared to control and lactate. In summary, these experiments indicate that pyruvate exposure prior to glucose deprivation significantly increased the energy buffering capacity of hippocampal slices, particularly by enhancing internal glycogen stores, delaying synaptic failure during glucose deprivation by maintaining ATP levels, and minimizing the decrease in the levels of NAD(P)H.
Introduction
Mature brain depends on glucose as a primary metabolic substrate, which is either metabolized directly by neurons or metabolized to lactate in glia and exported to neurons as an energy source (Brown et al., 2003; Dringen et al., 1993; Pellerin et al., 1998; Wender et al., 2000) . Brain can store glucose in the form of glycogen in astrocytes, which can serve as an immediate energy source when glucose supply is limited. However, brain normally has low glycogen levels (3-12 μmol glycosyl units/g tissue), insufficient to support neuronal function even for a short period of exposure to low glucose concentration (Cataldo and Broadwell, 1986; Choi and Gruetter, 2003; Cruz and Dienel, 2002; Dringen and Hamprecht, 1992; Sang Won et al., 2007; Wender et al., 2000) . Although astrocytes have glucose 6-phosphatase activity (Ghosh et al., 2005) , astroglia only extrude glucose (from glycogen breakdown) in some limited situations (Eyre et al., 1994; Walz and Mukerji, 1988) . Neurons therefore primarily rely on astrocytic-derived lactate resulting from glycogen breakdown for energy support during glucose deprivation (Brown et al., 2005; Dringen et al., 1993; Pellerin and Magistretti, 1994; Pellerin et al., 2007; Sickmann et al., 2009; Walz and Mukerji, 1988) . In addition to astrocyte-derived lactate brain can also utilize ketone bodies, lactate and pyruvate derived from systemic sources during hypoglycemia.
Although lactate can maintain neuronal synaptic function, pyruvate, another key intermediate in the metabolism of glucose, may be a better energy substrate after hypoglycemia than lactate in neurons (Suh et al., 2005) . For example, depletion of cytoplasmic NAD + by poly (ADPribose) polymerase-1 (PARP-1) activation during hypoglycemia can render neurons unable to use glucose and lactate (Suh et al., 2005) whereas exogenous pyruvate can still be effectively metabolized to produce ATP. Supplementation with pyruvate can also support neuronal function, particularly in the absence of glucose (Maus et al., 1999) . However, any protective effect of systemic pyruvate depends
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Abbreviations: fEPSP, field excitatory postsynaptic potential; A1, adenosine receptor 1; DPCPX, 8-cyclopentyl-1,3-dipropylxanthine; DAB, 1, 4-dideoxy-1,4-imino-D-arabinitol; NJM, 1-deoxyjirinomycin; ACSF, artificial cerebrospinal fluid; CA1, cornu ammonis region 1; DG, dentate gyrus; SR, stratum radiatum; AG, amyloglucosidase; glc, glucose; pyr, pyruvate; con, control; GIs, glycogenolysis inhibitors; ROI, region of interest; MCT, monocarboxylate transporter.
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